chief executive officer, F-star Therapeutics
Dr Eliot Forster has served as F-star’s Chief Executive Officer since October 2018 and as a member of F-star’s Board of Directors since May 2019. Dr Forster also serves on the boards of directors of F-star Alpha, F-star Beta, F-star Biotechnology, F-star Delta and director for F-star GmbH since May 2019. From January 2015 to February 2018, Dr Forster served as Chief Executive Officer of Immunocore Limited. Prior to that, he serves as Chief Executive Officer of Creabilis SA (which was subsequently acquired by Sienna Biopharmaceuticals, Inc) from May 2010 to January 2015. From May 2007 to May 2010, Dr Forster served as Chief Executive Officer of Solace Pharmaceuticals Inc and Asia at Pfizer Inc from 1996 to 2007. Since June 2018, Dr Forster has served as non-executive chairman of Avacta Group place, which is publicly traded on the London Stock Exchange.
Dr Forster is an Honorary Visiting Professor of the Pharmacology and Physiology Department at the University of Liverpool, an honorary professor at the Health Research, MedCity and the National Genomics Board. He holds a PhD from University of Liverpool, an MBA from Henley Management College, and a BSc with honours from University of Liverpool.